Search results
Found 7361 matches for
An internationally recognised centre of excellence for biomedical and clinical research and teaching
Regular meat consumption linked with a wide range of common diseases
2 March 2021
Regular meat consumption is associated with a range of diseases that researchers had not previously considered, according to a large, population-level study conducted by a team at the University of Oxford.
New data show vaccines reduce severe COVID-19 in older adults
2 March 2021
New data show both Oxford / AstraZeneca vaccine and the Pfizer-BioNTech vaccines significantly reduce severe COVID-19 in older adults.
Singula Bio, a new Oxford spin-out company - Cancer need not be fatal
25 February 2021
Singula Bio, a bold new seed-stage biotechnology company spun out of Oxford University, has been launched with the intention of helping show that cancer need not be fatal. Led by three Oxford cancer specialists, the firm is aims to become a world leader in therapies to use against difficult-to-treat solid malignancies such as ovarian cancer - using the body’s own immune system to fight previously fatal cancers.
Call for Mentors: Council for At-Risk Academics (CARA)
25 February 2021
Major rise in public support for COVID vaccine – Oxford study
24 February 2021
More than three quarters of people in the UK now say they are ’very likely’ to have the vaccine – up from 50% among the same group of survey respondents five months ago –according to a two-wave Oxford University survey published today.
Coronavirus vaccination linked to substantial reduction in hospitalisation, real-world data suggests
22 February 2021
The first study to describe the effects in real-world communities of the Oxford coronavirus vaccine has been reported in a pre-print publication today, showing a clear reduction in the risk of hospitalisation from COVID-19 amongst those who have received the vaccine.
World’s largest clinical trial for COVID-19 treatments expands internationally
18 February 2021
The Randomised Evaluation of COVID-19 Therapy (RECOVERY) Trial, the world’s largest clinical trial for COVID-19 treatments, has now expanded internationally with Indonesia and Nepal among the first countries to join. The first patients have been recruited to RECOVERY International.
Reprogramming tumour cells using an antimalarial drug
18 February 2021
Results from the ATOM clinical trial at the University of Oxford have shown that the anti-malarial drug Atovaquone can reduce very low oxygen tumour environments. This has the potential to make cancers behave less aggressively and to improve the impact of everyday cancer treatments.
Oxford-led technology to help those at high risk from Covid-19
16 February 2021
More people in England at high risk from Covid-19 will get priority access to vaccines thanks to new technology developed by a University of Oxford-led team of researchers that can identify those who may be most vulnerable to the virus.
Oxford to collaborate with Janssen to map the cellular landscape of immune mediated disorders
16 February 2021
The University of Oxford announced today that it has entered into a strategic collaboration with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson.
World Health Organization lists Oxford coronavirus vaccine for emergency use
15 February 2021
The Oxford / AstraZeneca vaccine has today been granted Emergency Use Listing (EUL) by the World Health Organization (WHO) for active immunisation to prevent COVID-19 in individuals 18 years of age and older, including those over 65.
How monkeys and humans make novel choices
15 February 2021
Dr Alessandro Bongioanni, Postdoctoral Research Associate in the Department of Experimental Psychology, writes for the Oxford Science Blog on the way humans and other primates make first-time choices.
Oxford University extends COVID-19 vaccine study to children
12 February 2021
The University of Oxford, together with three partner sites in London, Southampton and Bristol, is to launch the first study to assess the safety and immune responses in children and young adults of the ChAdOx1 nCoV-19 coronavirus vaccine.
Exscientia and the University of Oxford announce partnership to develop treatments for Alzheimer’s disease
12 February 2021
Neuroinflammation collaboration targeting inflammasome steps-up-the-pace in race for Alzheimer’s disease medicines that alleviate the burden of devastating disease
Tocilizumab reduces deaths in patients hospitalised with COVID-19
11 February 2021
The Randomised Evaluation of COVID-19 Therapy (RECOVERY) has demonstrated that an anti-inflammatory treatment, tocilizumab, reduces the risk of death when given to hospitalised patients with severe COVID-19. The study also showed that tocilizumab shortens the time until patients are successfully discharged from hospital and reduces the need for a mechanical ventilator.
Study reveals the safety of bisphosphonates in chronic kidney disease
10 February 2021
The results of an observational study published in JMBR and funded by the Health Technology Assessment Programme shows that bisphosphonate use is associated with a greater risk of chronic kidney disease progression.
Drug trial that could improve respiratory recovery from COVID-19 now underway
10 February 2021
A clinical trial has commenced this week to test whether a drug called Almitrine can help people who are seriously ill with COVID-19 to recover from the disease.